FDA AdComm Sets Date to Assess GSK’s Plans for Jemperli in Rectal Cancer
The FDA has set a Feb. 9 meeting for its Oncologic Drugs Advisory Committee (ODAC) to discuss whether GSK’s clinical development plans for Jemperli.
The Home of the Life Sciences Industry
Vertex Gives Update on Next-in-Class CF Therapy Amid Demand for Generics
Amid growing demands for generic versions of Vertex’s Trikafta, the company provided an update on the late-stage clinical development of its next-in-class triple combination for cystic fibrosis.
